Brokerages Set Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Price Target at $29.14

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) have been assigned an average recommendation of “Moderate Buy” from the eight ratings firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $29.1429.

Several analysts have commented on the stock. Stifel Nicolaus set a $30.00 target price on shares of Kestra Medical Technologies in a research report on Friday, December 12th. Piper Sandler upped their price objective on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. The Goldman Sachs Group raised their target price on Kestra Medical Technologies from $22.00 to $25.00 and gave the company a “neutral” rating in a report on Saturday, December 13th. Wall Street Zen lowered Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Sunday, September 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Kestra Medical Technologies in a report on Wednesday, December 24th.

Insider Activity at Kestra Medical Technologies

In other Kestra Medical Technologies news, insider Traci S. Umberger sold 10,500 shares of the stock in a transaction on Monday, December 29th. The shares were sold at an average price of $26.69, for a total value of $280,245.00. Following the completion of the sale, the insider directly owned 136,633 shares of the company’s stock, valued at $3,646,734.77. This represents a 7.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $26.59, for a total transaction of $398,850.00. Following the completion of the sale, the insider owned 409,786 shares of the company’s stock, valued at approximately $10,896,209.74. The trade was a 3.53% decrease in their position. The disclosure for this sale is available in the SEC filing. 3.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of KMTS. Yu Fan acquired a new stake in shares of Kestra Medical Technologies during the 1st quarter valued at about $56,880,000. Alliancebernstein L.P. lifted its stake in Kestra Medical Technologies by 13.7% during the third quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock worth $35,449,000 after purchasing an additional 179,885 shares during the period. Eventide Asset Management LLC boosted its holdings in Kestra Medical Technologies by 285.7% during the second quarter. Eventide Asset Management LLC now owns 1,060,557 shares of the company’s stock valued at $17,584,000 after purchasing an additional 785,557 shares in the last quarter. Brown Advisory Inc. grew its stake in shares of Kestra Medical Technologies by 5.4% in the 2nd quarter. Brown Advisory Inc. now owns 580,025 shares of the company’s stock valued at $9,617,000 after purchasing an additional 29,607 shares during the period. Finally, Millennium Management LLC acquired a new position in shares of Kestra Medical Technologies in the 1st quarter worth approximately $11,036,000.

Kestra Medical Technologies Trading Down 8.0%

Shares of NASDAQ KMTS opened at $24.39 on Wednesday. The business has a 50 day simple moving average of $26.28 and a 200 day simple moving average of $21.58. Kestra Medical Technologies has a 52 week low of $13.25 and a 52 week high of $30.00. The stock has a market cap of $1.42 billion and a price-to-earnings ratio of -7.69. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.47 and a current ratio of 5.47.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.